Percutaneous autologous venous valve transplantation: short-term feasibility study in an ovine model.
BACKGROUND
Limited experience with bioprosthetic venous valve percutaneously inserted into femoral veins in 15 patients has been promising in short-term results only to show disappointing long-term results. Percutaneous autogenous venous valve (PAVV) transplantation was explored in an ovine model as a possible alternative treatment.


METHODS
PAVV consisted of a vein segment containing a valve that was attached to a stent template. The stent templates (n = 9) were designed and hand made in our research laboratory. They consist of two stainless steel square stents 13 or 15 mm in diameter to fit the ovine jugular veins (JV), which ranges from 10 to 15 mm in diameter. A valve-containing segment of JV was harvested and attached with sutures and barbs inside the stent template (n = 9). The valve devices were then manually folded and front loaded inside the 4 cm chamber of the 13F delivery sheath and delivered into the contralateral JV by femoral vein approach. Transplanted PAVVs were studied by immediate and 3 months venograms. Animals were euthanized at 3 months, and jugular veins harvested to perform angioscopic evaluations in vitro.


RESULTS
PAVV transplantation was successful in all nine animals. Good valve function with no reflux was observed on immediate and 3 months venograms in eight valves. The transplanted maximal JV diameter ranged from 10.2 mm to 15.4 mm (mean 13.1 +/- 1.5 mm). Venoscopic examination revealed intact, flexible, nonthickened valve leaflets in eight specimens. One PAVV exhibited normal function of one leaflet only; the other cusp was accidentally cut during the transplantation procedure. All transplanted autologous valves were free of thrombus and incorporated into the vein wall of the host vessel.


CONCLUSIONS
This study demonstrated that autogenous valve transplants remained patent and competent without long-term anticoagulation for up to 3 months. The percutaneous autogenous venous valve may provide in future minimally invasive treatment for patients with chronic deep venous insufficiency, but long-term studies need to be done to document its continued patency and function.
Pavcnik
Dusan
D
Oregon Health and Science University, Dotter Interventional Institute, Portland, OR 97239, USA. pavcnikd@ohsu.edu
Yin
Qiang
Q
Uchida
Barry
B
Park
Won Kyu
WK
Hoppe
Hanno
H
Kim
Man Duck
MD
Keller
Frederick S
FS
Rösch
Josef
J
D000818:Animals; D001705:Bioprosthesis; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation; D005240:Feasibility Studies; D007601:Jugular Veins / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D008943:Mitral Valve / Q000637:transplantation*; D023421:Models, Animal; D011474:Prosthesis Design; D012756:Sheep; D015607:Stents; D014182:Transplantation, Autologous; D014654:Vascular Patency